Administration of vepafestinib resulted in a dose-dependent decrease in growth of NIH-3T3-RET xenograft tumors (Fig. 5a, left), with all dosages of vepafestinib tested resulting in a significant reduction in tumor volume (Fig. 5a, middle). The gene discussed is RET; the disease is neoplasm.